Healthcare / Drug Manufacturers - Specialty & GenericCanadian Sec
$0.01
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 23%
FCF escenarios
weak_data · normalized FCF $-4.0M · quality 66.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
18/100
F
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$2M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-156.4%
↓Gross Margin
31.9%
↓Debt/Equity
0.01
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-4.8%
FCF CAGR
—
FCF margin
-31.5%
FCF / Net income
0.12x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $3.4M · net income $-8.9M · FCF $-1.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $3.4M | $3.4M | $4.3M | $5.1M | $3.9M |
| Net Income | $-8.9M | $-8.9M | $-16.5M | $-7.7M | $-21.0M |
| EBITDA | $-7.9M | $-7.9M | $-15.2M | $-6.3M | $-19.9M |
| EPS | -0.07 | -0.07 | -0.14 | -0.06 | -0.17 |
| Gross Margin | 31.9% | 31.9% | 40.6% | 7.8% | 13.6% |
| Operating Margin | -127.7% | -127.7% | -155.4% | -139.5% | -203.4% |
| Net Margin | -265.1% | -265.1% | -380.1% | -152.4% | -537.8% |
| Balance Sheet | |||||
| Debt/Equity | 0.01 | 0.01 | 0.01 | 0.01 | 0.02 |
| Current Ratio | 0.66 | 0.66 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-1.1M | $-1.1M | $-4.0M | $-4.4M | $-6.1M |
| Returns | |||||
| ROE | -156.4% | -156.4% | -121.0% | -26.2% | -58.9% |
| Valuation | |||||
| P/B | 0.31 | 0.31 | 0.09 | 0.33 | 0.69 |
| Growth & Yield | |||||
| Revenue Growth | -22.6% | -22.6% | -14.3% | 30.0% | — |
| EPS Growth | 46.0% | 46.0% | -116.6% | 62.6% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+50.0%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.14 → -0.07
Residual
+50.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.